🏥 Doctors, Drugs & Deals: Who Really Influences Prescriptions?

When marketing meets medicine, ethics matter. But in India’s public hospitals, access—not influence—decides which drugs get prescribed. Last week, I was speaking to a junior doctor at a government hospital. He laughed when I asked if medical reps still visit. “Rarely,” he said. “The meds we prescribe? They’re the ones available in the pharmacy downstairs. No use hearing about drugs I can’t even give.” That struck me. Because the big pharma debate is heating up again. The Health Ministry has banned medical reps from entering government hospitals — to stop undue influence and keep patient care neutral. The Indian Pharmaceutical Alliance is protesting this “blanket ban.” Their argument? MRs aren’t just marketers — they’re educators too. Cut them off, and doctors miss out on vital drug updates. But let’s zoom out. In public hospitals, medicines come through bulk procurement via tender — the lowest bidder gets the deal, not the best talker. Even if a doctor wants to prescribe a promoted brand, it won’t be stocked. The result? Tender trumps influence. So, the real battleground isn’t doctor prescriptions — it’s the procurement room. 💹 What This Means for Investors If you're watching this unfold from a stock market lens, shift your focus. 🟢 Stocks that benefit? Online Tender & Procurement Enablers (like Coforge

, Infibeam Avenues) Generics + Contract Manufacturers (like Alkem Labs , JB Chemicals, IPCA Labs) API Manufacturers (like Divi’s, Neuland Labs) who benefit from bulk government contracts These companies don’t rely on fancy field forces. They win through efficiency, quality, and cost — and in an ethical, regulated future, that’s where the moat lies.